ANXA1 and melanoma: Our study is the first to demonstrate that elevated protein expression of ANXA1, CAV-1 or EphA2 correlates with dasatinib sensitivity in melanoma cells in vitro. Statistical analysis of high versus low expression of the biomarkers in the cell line panel suggests that EphA2 alone or in combination with ANXA1 or CAV-1 may have the strongest predictive power.